Clinical Trial Update: Sintilimab in Combination With Nab-paclitaxel in Patients With HNSCC (Head and Neck Squamous Cell Carcinoma ) [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating Sintilimab in combination with Nab-paclitaxel for head and neck squamous cell carcinoma is in early stages with unknown status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Nab-paclitaxel (paclitaxel protein-bound)
• Sintilimab (sintilimab)

Snippet

Sponsor: Shengyu Zhou | Conditions: Head and Neck Squamous Cell Cancer | Phase 2 | Status: UNKNOWN